Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Can GLP-1 Drugs Make Botox Wear Off Sooner?
A computer model predicts shorter botulinum toxin A durability with GLP-1 drugs. It is a hypothesis, not proof from patient care.
Semaglutide dose changes: label context
A community dose-change post cannot tell another reader what to do. Product labels and a prescribing clinician provide the relevant context.
Semaglutide Product Switches and Diarrhea
What Ozempic and Wegovy labels say about diarrhea, why a symptom report cannot prove causation, and when official guidance calls for assessment.
Wegovy Symptoms: What the Label Says
A guide to Wegovy's official adverse-reaction and warning language, and why a forum report cannot diagnose what caused one person's symptoms.
Peptide Reaction When to Seek Care
Severe or persistent symptoms after a peptide injection need clinical assessment, not a crowd diagnosis or a guessed cause.
Retatrutide Trial Results Explained
A Phase 2 retatrutide trial reported large average weight reductions. Here is what that result can and cannot tell an individual reader.
Cardiovascular and liver care gaps
A new review examines how access barriers can shape cardiovascular and metabolic liver disease care, including selected MASH treatments.
GLP-1 drugs and hidradenitis suppurativa
A Danish cohort found more GLP-1 receptor agonist use in hidradenitis suppurativa, but it did not establish a direct treatment benefit.
A Heart Failure AI Comment, Explained
A new heart failure comment discusses advanced imaging and AI, but its PubMed record does not establish a semaglutide finding.
Incretin Care in Cardiology: Study Findings
A single cardiology program tracked incretin prescribing in high-risk patients. Its results describe routine care, not proof of treatment effects.
Medicare prescription payment plans
A modelling study shows when Medicare prescription payment plans may smooth Part D costs and when later bills can become more concentrated.
PT-141 Headache and Congestion
Headache and nasal congestion appeared in Vyleesi trials, but a forum report cannot diagnose an individual reaction or verify a PT-141 product.